Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Growth gains from selective breeding in a spruce hybrid zone do not compromise local adaptation to climate.

MacLachlan IR, Yeaman S, Aitken SN.

Evol Appl. 2017 Sep 3;11(2):166-181. doi: 10.1111/eva.12525. eCollection 2018 Feb.

2.

siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease.

Thi EP, Mire CE, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Cross RW, Kondratowicz AS, Fenton KA, MacLachlan I, Geisbert TW.

J Clin Invest. 2017 Dec 1;127(12):4437-4448. doi: 10.1172/JCI96185. Epub 2017 Nov 6.

3.

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA.

Thi EP, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Fenton KA, Kondratowicz AS, MacLachlan I, Geisbert TW, Mire CE.

Nat Microbiol. 2016 Aug 22;1(10):16142. doi: 10.1038/nmicrobiol.2016.142.

4.

Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Thi EP, Mire CE, Lee AC, Geisbert JB, Zhou JZ, Agans KN, Snead NM, Deer DJ, Barnard TR, Fenton KA, MacLachlan I, Geisbert TW.

Nature. 2015 May 21;521(7552):362-5. doi: 10.1038/nature14442. Epub 2015 Apr 22.

5.

Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.

Thi EP, Mire CE, Ursic-Bedoya R, Geisbert JB, Lee ACH, Agans KN, Robbins M, Deer DJ, Fenton KA, MacLachlan I, Geisbert TW.

Sci Transl Med. 2014 Aug 20;6(250):250ra116. doi: 10.1126/scitranslmed.3009706.

6.

Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.

Lee YH, Seo D, Choi KJ, Andersen JB, Won MA, Kitade M, Gómez-Quiroz LE, Judge AD, Marquardt JU, Raggi C, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS.

Cancer Res. 2014 Sep 1;74(17):4752-61. doi: 10.1158/0008-5472.CAN-13-3531. Epub 2014 Jun 23.

7.

Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy.

Dallas A, Ilves H, Ma H, Chin DJ, Maclachlan I, Klumpp K, Johnston BH.

J Virol. 2014 May;88(9):4647-56. doi: 10.1128/JVI.00105-14. Epub 2014 Jan 29.

8.

Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers.

Ma H, Dallas A, Ilves H, Shorenstein J, MacLachlan I, Klumpp K, Johnston BH.

Gastroenterology. 2014 Jan;146(1):63-6.e5. doi: 10.1053/j.gastro.2013.09.049. Epub 2013 Sep 27.

9.

Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice.

Dallas A, Ilves H, Shorenstein J, Judge A, Spitler R, Contag C, Wong SP, Harbottle RP, Maclachlan I, Johnston BH.

Mol Ther Nucleic Acids. 2013 Sep 17;2:e123. doi: 10.1038/mtna.2013.50.

10.

Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA.

Ursic-Bedoya R, Mire CE, Robbins M, Geisbert JB, Judge A, MacLachlan I, Geisbert TW.

J Infect Dis. 2014 Feb 15;209(4):562-70. doi: 10.1093/infdis/jit465. Epub 2013 Aug 29.

11.

Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response.

Lee YH, Judge AD, Seo D, Kitade M, Gómez-Quiroz LE, Ishikawa T, Andersen JB, Kim BK, Marquardt JU, Raggi C, Avital I, Conner EA, MacLachlan I, Factor VM, Thorgeirsson SS.

Oncogene. 2011 Oct 6;30(40):4175-84. doi: 10.1038/onc.2011.126. Epub 2011 Apr 18.

12.

Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma.

Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, Marquardt JU, Kitade M, Durkin ME, Raggi C, Woo HG, Conner EA, Avital I, Maclachlan I, Factor VM, Thorgeirsson SS.

Cancer Res. 2010 Nov 1;70(21):8264-9. doi: 10.1158/0008-5472.CAN-10-0749. Epub 2010 Oct 19.

13.

Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, Johnson JC, de Jong S, Tavakoli I, Judge A, Hensley LE, Maclachlan I.

Lancet. 2010 May 29;375(9729):1896-905. doi: 10.1016/S0140-6736(10)60357-1.

PMID:
20511019
14.

Rational design of cationic lipids for siRNA delivery.

Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ.

Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17.

PMID:
20081866
15.

siRNA and innate immunity.

Robbins M, Judge A, MacLachlan I.

Oligonucleotides. 2009 Jun;19(2):89-102. doi: 10.1089/oli.2009.0180. Review.

PMID:
19441890
16.

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.

Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLachlan I.

J Clin Invest. 2009 Mar;119(3):661-73. doi: 10.1172/JCI37515. Epub 2009 Feb 23.

17.

Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation.

Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L, McClintock K, MacLachlan I.

Hum Gene Ther. 2008 Oct;19(10):991-9. doi: 10.1089/hum.2008.131.

PMID:
18713023
18.

siRNAs with guts.

Maclachlan I.

Nat Biotechnol. 2008 Apr;26(4):403-5. doi: 10.1038/nbt0408-403. No abstract available.

PMID:
18392024
19.

Overcoming the innate immune response to small interfering RNA.

Judge A, MacLachlan I.

Hum Gene Ther. 2008 Feb;19(2):111-24. doi: 10.1089/hum.2007.179. Review.

PMID:
18230025
20.

2'-O-methyl-modified RNAs act as TLR7 antagonists.

Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I.

Mol Ther. 2007 Sep;15(9):1663-9. Epub 2007 Jun 19.

21.

Lipid encapsulation enables the effective systemic delivery of polyplex plasmid DNA.

Heyes J, Palmer L, Chan K, Giesbrecht C, Jeffs L, MacLachlan I.

Mol Ther. 2007 Apr;15(4):713-20. Epub 2007 Feb 13.

22.

Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference.

Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-DiCaprio K, Fritz EA, Jahrling PB, McClintock K, Phelps JR, Lee AC, Judge A, Jeffs LB, MacLachlan I.

J Infect Dis. 2006 Jun 15;193(12):1650-7. Epub 2006 May 10.

PMID:
16703508
23.

Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery.

Heyes J, Hall K, Tailor V, Lenz R, MacLachlan I.

J Control Release. 2006 May 15;112(2):280-90. Epub 2006 Mar 6.

PMID:
16603272
24.

RNAi-mediated gene silencing in non-human primates.

Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I, Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I, Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M, Vornlocher HP, MacLachlan I.

Nature. 2006 May 4;441(7089):111-4. Epub 2006 Mar 26.

PMID:
16565705
25.

Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.

Judge AD, Bola G, Lee AC, MacLachlan I.

Mol Ther. 2006 Mar;13(3):494-505. Epub 2005 Dec 15.

26.

Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

Judge A, McClintock K, Phelps JR, Maclachlan I.

Mol Ther. 2006 Feb;13(2):328-37. Epub 2005 Nov 7.

27.

"Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles"

Maclachlan I, Cullis P.

Adv Genet. 2005;53PA:157-188.

PMID:
16243063
28.

"Diffusible-PEG-lipid stabilized plasmid lipid particles".

MacLachlan I, Cullis P.

Adv Genet. 2005;53:157-88. Review.

PMID:
16240993
29.

Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids.

Heyes J, Palmer L, Bremner K, MacLachlan I.

J Control Release. 2005 Oct 3;107(2):276-87.

PMID:
16054724
30.

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B.

Nat Biotechnol. 2005 Aug;23(8):1002-7. Epub 2005 Jul 24.

31.

Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression.

Ambegia E, Ansell S, Cullis P, Heyes J, Palmer L, MacLachlan I.

Biochim Biophys Acta. 2005 May 20;1669(2):155-63. Epub 2005 Feb 24.

32.

A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA.

Jeffs LB, Palmer LR, Ambegia EG, Giesbrecht C, Ewanick S, MacLachlan I.

Pharm Res. 2005 Mar;22(3):362-72.

PMID:
15835741
33.

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA.

Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I.

Nat Biotechnol. 2005 Apr;23(4):457-62. Epub 2005 Mar 20.

PMID:
15778705
34.

Factors limiting autogene-based cytoplasmic expression systems.

Finn J, MacLachlan I, Cullis P.

FASEB J. 2005 Apr;19(6):608-10. Epub 2005 Jan 26.

PMID:
15677338
35.

An enhanced autogene-based dual-promoter cytoplasmic expression system yields increased gene expression.

Finn J, Lee AC, MacLachlan I, Cullis P.

Gene Ther. 2004 Feb;11(3):276-83.

PMID:
14737087
36.

Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids.

Palmer LR, Chen T, Lam AM, Fenske DB, Wong KF, MacLachlan I, Cullis PR.

Biochim Biophys Acta. 2003 Apr 1;1611(1-2):204-16.

37.

Stabilized plasmid-lipid particles: a systemic gene therapy vector.

Fenske DB, MacLachlan I, Cullis PR.

Methods Enzymol. 2002;346:36-71.

PMID:
11883080
38.

Analysis of differential lipofection efficiency in primary and established myoblasts.

Pampinella F, Lechardeur D, Zanetti E, MacLachlan I, Benharouga M, Lukacs GL, Vitiello L.

Mol Ther. 2002 Feb;5(2):161-9.

39.

Progress towards a synthetic virus for systemic gene therapy.

MacLachlan I, Cullis P, Graham RW.

Curr Opin Mol Ther. 1999 Apr;1(2):252-9. Review.

PMID:
11715948
40.

Long-circulating vectors for the systemic delivery of genes.

Fenske DB, MacLachlan I, Cullis PR.

Curr Opin Mol Ther. 2001 Apr;3(2):153-8. Review.

PMID:
11338928
41.

Stabilized plasmid-lipid particles: construction and characterization.

Wheeler JJ, Palmer L, Ossanlou M, MacLachlan I, Graham RW, Zhang YP, Hope MJ, Scherrer P, Cullis PR.

Gene Ther. 1999 Feb;6(2):271-81.

42.

Cationic lipid-mediated transfection of cells in culture requires mitotic activity.

Mortimer I, Tam P, MacLachlan I, Graham RW, Saravolac EG, Joshi PB.

Gene Ther. 1999 Mar;6(3):403-11.

43.
44.
45.

Characterization of the Japanese quail oocyte receptor for very low density lipoprotein and vitellogenin.

Elkin RG, MacLachlan I, Hermann M, Schneider WJ.

J Nutr. 1995 May;125(5):1258-66.

PMID:
7738685
46.

Riboflavinuria in the rd chicken. 5'-splice site mutation in the gene for riboflavin-binding protein.

MacLachlan I, Nimpf J, White HB 3rd, Schneider WJ.

J Biol Chem. 1993 Nov 5;268(31):23222-6.

47.

The relationship between cognitive failures, psychoneurotic symptoms and sex.

Hood BM, MacLachlan IM, Fisher S.

Acta Psychiatr Scand. 1987 Jul;76(1):33-5.

PMID:
3630752
48.

Community nursing. Immigrants: do we understand them enough to help them? 4. Communication.

Fitzgerald MJ, MacLachlan ID.

Nurs Mirror. 1978 Aug 17;147(7):34. No abstract available.

PMID:
249496
49.

Immigrants: do we understand them enough to help them? 3: Foreground.

Fitzgerald MJ, MacLachlan ID.

Nurs Mirror. 1978 Aug 10;147(6):37-8. No abstract available.

PMID:
248809
50.

Immigrants: do we understand them enough to help them? 1. Identifying the problem.

Fitzgerald MJ, MacLachlan ID.

Nurs Mirror. 1978 Jul 27;147(4):35-6. No abstract available.

PMID:
248787

Supplemental Content

Loading ...
Support Center